Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10972478,specific activity,"In an in vivo study female Sprague Dawley rats were pretreated with 100 mg/kg of dexrazoxane by intravenous injection 1 h before the injection of 14C-doxorubicin (specific activity 0.4 microCi/mg, 10 mg/kg).",Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972478/),[μci] / [mg],0.4,8782,DB00380,Dexrazoxane
less,20484616,CL(CR),Modeling study results suggested that equivalent exposure could be achieved if dosing was halved in subjects with CL(CR) less than 40 mL/min compared with controls.,Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484616/),[ml] / [min],40,9704,DB00380,Dexrazoxane
,1433357,terminal half-life,Doxorubicin's estimated terminal half-life was 39.5 +/- 18.3 (mean +/- SD) hours; the area under the curve for plasma concentration of drug x time (AUC) was 1.74 +/- 0.40 (micrograms/microL) x hour.,Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),h,39.5,61210,DB00380,Dexrazoxane
,1433357,area under the curve for plasma concentration of drug x time (AUC),Doxorubicin's estimated terminal half-life was 39.5 +/- 18.3 (mean +/- SD) hours; the area under the curve for plasma concentration of drug x time (AUC) was 1.74 +/- 0.40 (micrograms/microL) x hour.,Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),[μg] / [h·μl)],1.74,61211,DB00380,Dexrazoxane
,1433357,Total-body clearance,"Total-body clearance was 598 +/- 142 microL/m2 per minute (N = 20), and it did not vary with ADR-529 dose.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),[μl] / [m2·min],598,61212,DB00380,Dexrazoxane
,1433357,distribution,"Estimated distribution and elimination phase half-lives for plasma ADR-529 were 0.46 +/- 0.30 hours and 4.16 +/- 2.94 hours, respectively.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),h,0.46,61213,DB00380,Dexrazoxane
,1433357,elimination phase half-lives,"Estimated distribution and elimination phase half-lives for plasma ADR-529 were 0.46 +/- 0.30 hours and 4.16 +/- 2.94 hours, respectively.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),h,4.16,61214,DB00380,Dexrazoxane
,1433357,Total-body clearance,"Total-body clearance was 111 +/- 87 microL/m2 per minute (N = 18); AUC was linear (r2 = .92), and the clearance rate was constant (r2 = .18) from 60 to 900 mg/m2.",Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433357/),[μl] / [m2·min],111,61215,DB00380,Dexrazoxane
,9768830,steady-state DEX plasma concentrations,Results of pharmacokinetic studies in support of the trial have found that steady-state DEX plasma concentrations in the range of 4 to 5 micromol/L can be achieved safely.,Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768830/),[μM] / [l],4 to 5,69641,DB00380,Dexrazoxane
,8866044,terminal half-life,The terminal half-life ranged between 1.1 and 1.3 h and the apparent steady-state distribution volume was 0.67 L kg-1.,Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),h,1.1 and 1.3,83262,DB00380,Dexrazoxane
,8866044,apparent steady-state distribution volume,The terminal half-life ranged between 1.1 and 1.3 h and the apparent steady-state distribution volume was 0.67 L kg-1.,Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),[l] / [kg],0.67,83263,DB00380,Dexrazoxane
,8866044,systemic clearance (CL),"The systemic clearance (CL) ranged from 10.3 to 11.5 mL min-1 kg-1, while estimates of renal clearance approximated the glomerular filtration rate (GFR approximately 3.2-4.9 mL min-1 kg-1).",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),[ml] / [kg·min],10.3 to 11.5,83264,DB00380,Dexrazoxane
,8866044,blood cell to plasma partitioning ratio,The blood cell to plasma partitioning ratio was approximately 0.517 and drug was essentially unbound to plasma proteins (fu approximately 0.95).,Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.517,83265,DB00380,Dexrazoxane
,8866044,fu,The blood cell to plasma partitioning ratio was approximately 0.517 and drug was essentially unbound to plasma proteins (fu approximately 0.95).,Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.95,83266,DB00380,Dexrazoxane
,8866044,hepatic,"Dexrazoxane appeared to be subject to low organ extraction, since the hepatic and renal drug extraction ratios were on the order of 0.228 +/- 0.054 and 0.184 +/- 0.024, respectively.",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.228,83267,DB00380,Dexrazoxane
,8866044,renal,"Dexrazoxane appeared to be subject to low organ extraction, since the hepatic and renal drug extraction ratios were on the order of 0.228 +/- 0.054 and 0.184 +/- 0.024, respectively.",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.228,83268,DB00380,Dexrazoxane
,8866044,renal,"Dexrazoxane appeared to be subject to low organ extraction, since the hepatic and renal drug extraction ratios were on the order of 0.228 +/- 0.054 and 0.184 +/- 0.024, respectively.",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.184,83269,DB00380,Dexrazoxane
,8866044,drug extraction ratios,"Dexrazoxane appeared to be subject to low organ extraction, since the hepatic and renal drug extraction ratios were on the order of 0.228 +/- 0.054 and 0.184 +/- 0.024, respectively.",Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866044/),,0.184,83270,DB00380,Dexrazoxane
,9768822,alpha half-life,Pharmacologic studies of single agent dexrazoxane (originally studied as an antineoplastic agent) demonstrates an alpha half-life of approximately 30 minutes and a beta half-life of 2 to 4 hours.,Clinical pharmacology of dexrazoxane. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768822/),min,30,103351,DB00380,Dexrazoxane
,9768822,beta half-life,Pharmacologic studies of single agent dexrazoxane (originally studied as an antineoplastic agent) demonstrates an alpha half-life of approximately 30 minutes and a beta half-life of 2 to 4 hours.,Clinical pharmacology of dexrazoxane. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9768822/),h,2 to 4,103352,DB00380,Dexrazoxane
,17442993,steady-state G3139 concentration,"At this dose, the average (+/- standard deviation) steady-state G3139 concentration was 2.04 +/- 1 microg/mL, a concentration associated with biologic activity.","Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442993/),[μg] / [ml],2.04,113860,DB00380,Dexrazoxane
,1394799,half-lives,"The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0 +/- 0.5 and 32.2 +/- 12.8 min and 30.0 +/- 4.0 h, respectively.",Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394799/),min,3.0,122833,DB00380,Dexrazoxane
,1394799,half-lives,"The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0 +/- 0.5 and 32.2 +/- 12.8 min and 30.0 +/- 4.0 h, respectively.",Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394799/),min,32.2,122834,DB00380,Dexrazoxane
,1394799,half-lives,"The mean half-lives calculated for the fast and slow distributive and terminal elimination phases in the saline/doxorubicin group were 3.0 +/- 0.5 and 32.2 +/- 12.8 min and 30.0 +/- 4.0 h, respectively.",Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394799/),h,30.0,122835,DB00380,Dexrazoxane
,10071279,MTD,"The MTD of paclitaxel was 150 mg/m2, and adjunctive therapy with G-CSF was required to prevent febrile neutropenia.",Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071279/),[mg] / [m2],150,161889,DB00380,Dexrazoxane
,11410492,plasma CL(ss),"Dexrazoxane plasma CL(ss) and elimination t(1/2) were 7.2 +/- 1.6 l/h/m(2) and 2.0 +/- 0.8 h, respectively.",Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11410492/),[h·l] / [m(2],7.2,179963,DB00380,Dexrazoxane
,11410492,elimination t(1/2),"Dexrazoxane plasma CL(ss) and elimination t(1/2) were 7.2 +/- 1.6 l/h/m(2) and 2.0 +/- 0.8 h, respectively.",Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11410492/),h,2.0,179964,DB00380,Dexrazoxane
